Eagle Pharmaceuticals (EGRX) Tops Q1 EPS by 33c; Offers FY23 EPS Guidance

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $1.26, $0.33 better than the analyst estimate of $0.93. Revenue for the quarter came in at $66.3 million versus the consensus estimate of $63.29 million.

GUIDANCE:

Eagle Pharmaceuticals sees FY2023 EPS of $4.20-$4.53, versus the consensus of $4.21.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
• Jabil (JBL) Tops Q3 EPS by 8c, Offers Guidance
• FedEx (FDX) PT Lowered to $424 at Bernstein SocGen Group